1 / 13

Your logo

Your logo. Long-Term Reduction in Peripheral Blood HIV-1 Reservoirs Following Reduced-Intensity Allogeneic Stem Cell Transplantation in Two HIV-Infected Individuals.

whitney
Download Presentation

Your logo

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Your logo Long-Term Reduction in Peripheral Blood HIV-1 Reservoirs Following Reduced-Intensity Allogeneic Stem Cell Transplantation in Two HIV-Infected Individuals Timothy J. Henrich1,2, Gaia Sciaranghella3, Jonathan Z. Li1,2, Sebastien Gallien4, Vincent Ho5,2, Ann S. LaCasce5,2, and Daniel R. Kuritzkes1,2 1Brigham and Women's Hospital, Boston, MA; 2Harvard Medical School, Boston, MA; 3Ragon Institute of MGH, MIT, and Harvard, Boston, MA; 4 Hopital Saint-Louis, Paris, France; 5Dana-Farber Cancer Institute, Boston, MA.

  2. Background • One reported “functional cure” of HIV-1 infection: myeloablativeallogeneic HSCT from a homozygous ccr5Δ32donor1,2 • Several factors may have contributed to functional cure including pre-transplant myeloablative chemotherapy, GVHD, full engraftment of CCR5- donor cells • Cytotoxic chemotherapy alone insufficient to eliminate reservoirs as HIV-1 DNA persists after autologousHSCT3,4 • The long-term effects of allogeneic HSCT using CCR5+ stem cells have not been studied in detail 1Hutter et al. 2009; 2Allers et al. 2010; 3Simonelli et al. 2010; 4Cillo et al. 2011;

  3. Study Aims Study Aims: • Examine long-term changes in the peripheral HIV-1 reservoir following allogeneic HSCT in the setting of cART • Explore HIV-1 coreceptor usage, PBMC coreceptor expression and HIV-specific antibody responses pre- and post-HSCT Patients: 2 HIV-1 infected patients on combination ART who underwent reduced-intensity conditioning (RIC) allogeneic HSCT RIC = non-myeloablativechemotherapy, no total body irradiation or anti-thymocyte globulin

  4. Methods • Studied stored blood samples collected pre- and post-HSCT and prospectively collected samples (5 time points) • Quantified proviral HIV-1 DNA from peripheral blood mononuclear cells (PBMCs) and purified CD4+ T cells by real-time PCR • Quantified 2-LTR circles from PBMC episomal DNA • Quantified plasma viremia by a single-copy assay • Viral outgrowth assays using ~107 patient-derived CD4+ T cells and CD8 T cell-depleted lymphoblasts from an HIV-negative donor • CCR5 genotyping/flow cytometric quantification of CCR5 expression on CD3+ T lymphocytes • Genotypic and phenotypic determination of HIV-1 coreceptorusage • Quantified HIV-1-specific Ab levels & avidity

  5. Study Patients Patient A:Male with perinatally acquired HIV-1 on long-term ART 2006: Stage IV Hodgkin disease  standard treatment Disease recurrence  salvage therapy 2007: Autologous HSCT 2008: Relapse  RIC partially mismatched unrelated-donor HSCTcART: TDF/FTC/EFV 3-4 years pre-HSCT with undetectable VL Clinical course post-allogeneic HSCT

  6. Study Patients Patient B:Male with sexually acquired HIV-1 in mid-1980’s 2003: Large B-cell lymphoma  chemotherapy and cART started 2006: New stage IV Hodgkin lymphoma Disease recurrence  salvage therapy 2007: Autologous HSCT 2010: MDS (Tx-related)  RIC matched related-donor HSCTcART: TDF/FTC/RAL peri-transplant with undetectable VL Clinical course post-allogeneic HSCT

  7. Patient A Viral outgrowth assay negative day +1266 No 2-LTRs detected

  8. Patient B Viral outgrowth assay negative day +652 No 2-LTRs detected DLI= donor lymphocyte infusion

  9. CCR5 / Coreceptor Usage • Both patients heterozygous for ccr5Δ32mutation • PBMC homozygous wild-type for CCR5 after engraftment • Percentage of CCR5-expressing lymphocytes nearly doubled after full donor engraftment in Patient A (sufficient sample) • Full-length HIV-1 env amplified from proviral DNA at pre- and 1st post-HSCT PBMC samples (later timepoints negative) • V3-loop genotyping predicted CCR5 usage pre- and post-HSCT • R5 phenotype confirmed by tropism assay of pseudotyped viruses expressing PBMC-derived env

  10. Anti-HIV Ab Quantification Limited Sensitivity VITROS Assay Limiting-Antigen Avidiy Assay Patient A Patient B • HIV-specific Ab detected by VITROS assay pre- & post-HSCT • Decrease in Ab levels post-HSCT from diluted and undiluted plasma • Similar decrease in antigen avidity by limiting-antigen assay

  11. Summary & Conclusions • Allogeneic HSCT with RIC in the setting of suppressive ART led to a substantial and sustained reduction in the HIV-1 reservoir in PBMC - Reduction in proviral HIV-1 DNA correlated temporally with full donor engraftment • Engraftment of susceptible donor cells without infection adds supportive evidence that HIV-1 replication is fully suppressed by effective cART • Declining HIV-specific Ablevels/avidity provide further evidence for minimal persistence of HIV-1 antigen • Tissue sampling and analytic treatment interruption are necessary to fully assess the extent of HIV-1 reservoir reduction after allogeneic HSCT

  12. Acknowledgements BWH:Funding Sources: Members of the Kuritzkes Lab: NIH/NIAID 1K23AI098480-01A1 to TJH Zixin Hu UM1 AI068636 to DRK; P30 AI060354 Nina Lin U19 AI096109 to SGD Françoise Giguel Laura Lavoie AtheTsibris Members of the ID Division Blood Systems Research Institute/UCSF: Michael Busch ShealaKeeting Mila Lebedeva UCSF: Steven Deeks Harvard School of Public Health: Ronald Bosch (SDAC)

  13. Viral DNA Diversity Pre-HSCT Post-HSCT Patient A Single genome sequencing of full-length HIV-1 Env from PBMC DNA from pre- and 1st post-HSCT samples No major evolutionary changes observed following HSCT

More Related